New drugs in the treatment of germ cell tumors

Cancer and Chemotherapy Reviews

Volumn 2, Issue 4, 2007, Pages 232-240

  Piulats, Josep M ^a   del Muro, F Xavier García ^a   Lluch, Josep R Germà ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Chemotherapy; Germ cell tumors; Refractory; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN; STEM CELL FACTOR; TEMOZOLOMIDE; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VINBLASTINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER RELAPSE; CARCINOGENESIS; CHROMOSOME 7; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GENE EXPRESSION REGULATION; GENE LOCATION; GENE MUTATION; GERM CELL TUMOR; HUMAN; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE; PROTEIN TARGETING; REVIEW; SALVAGE THERAPY;

EID: 66149192851     PISSN: 1885740X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Oosterhuis JW, Looijenga LH. Testicular germ-cell tumors in a broader perspective. Nat Rev Cancer. 2005;5:210-22
2. Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol. 1990;8:1771-81.
3. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15:1377-99.
4. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ cell tumors of the testis: the experience of the Spanish Germ Cell Cancer Group. Eur Urol. 2002;42:553-62.
5. Stevens LC, Little CC. Spontaneous testicular teratomas in an inbred strain of mice. Proc Natl Acad Sci USA. 1954;40:1080-7.
6. Youngren KK, Coveney D, Peng X, et al. The Ter mutation in the dead-end gene causes germ cell loss and testicular germ cell tumors. Nature. 2005;435:360-4.
7. Walt H, Oosterhuis JW, Stevens LC. Experimental testicular germ cell tumorigenesis in mouse strains with and without spontaneous tumors differs from development of germ cell tumors of the adult human testis. Int J Androl. 1993;16:267-71.
8. Looijenga LH, Olie RA, van der Gaag I, et al. Seminomas of the canine testis. Counterpart of spermatocytic seminoma of men? Lab Invest. 1994;71:490-6.
9. Piulats JM, Vidal A, Nadal M, et al. Development of a human testicular germ cell tumor model in athymic mice. Proc Am Assoc Cancer Res. 2006;47:2760.
10. Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247-56.
11. Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer. 2003;97:1869-75.
12. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol. 1990;17:36-9.
13. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol. 1994;12:2277-83.
14. Bokemeyer C, Schmoll HJ, Natt F, et al. Preliminary results of a phase I/ II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol. 1994; 120:754-7.
15. Bokemeyer C, Bayer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol. 1996;7:31-4.
16. Nazario A, Amato RJ, Hutchinson L, et al. Paclitaxel in extensively pretreated non-seminomatous germ cell tumors. Urol Oncol. 1995;120:184-7.
17. Sandler AB, Cristou A, Fox S, et al. A phase II trial of paclitaxel in refractory germ cell tumors. Cancer. 1998;1381-6.
18. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413-18.
19. De Wit R, Louwarens M, de Mulder PH, et al. Management of intermediate-prognosis germ cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer. 1999;83:831-3.
20. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol. 1999;17: 509-11.
21. Bokemeyer C, Gerl A, Schöffski P, et al. Gemcitabine in patients with relapsed or cisptatin-refractory testicular cancer. J Clin Oncol. 1999;17:512-16.
22. Dunn TA, Schmoll HJ, Grunwald V, et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs. 1997;15:109-14.
23. Kollmannsberger C, Rick O, Derigs HG, et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2002;20:2031-7.
24. Miki T, Sawada M, Nonomura N, et al. Antitumor effect of CPT-11, a camptothecin derivate, on human testicular tumor xenografts in nude mice. Eur Urol. 1997;31:92-6.
25. Kollmannsberger C, Rick O, Klaproth H, et al. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer. 2002;87:729-32.
26. Pera MF, Köberle B, Masters JR. Exceptional sensitivity of testicular germ cell tumor cell lines to the new anticancer agent, temozolomide. Br J Cancer. 1995;71:904-6.
27. Varuni Kondagunta G, Bacik J, Schwartz L, et al. Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Invest New Drugs. 2004;22:177-9.
28. Germa-Lluch JR, Huddart R, Garcia del Muro X, et al. Phase II multicenter study of temozolomide in patients with resistant germ cell tumors. Proc Am Soc Clin Oncol. 2003;22:1757.
29. Oechsle K, Honecker F, Kollmannsberger C, et al. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. Anticancer Drugs. 2007; 18:273-6
30. Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23:6549-55.
31. Mead GM, Cullen MH, Huddart R, et al. A phase II trial of TIP given as second-line salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer. 2005;93:178-84.
32. Mardiak J, Sálek T, Svcová-Millá Z, et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma. 2005;52:497-501.
33. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide and cisplatin containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol. 1997; 15:2559-63.
34. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500-4.
35. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ cell tumors. N Engl J Med. 2007;357:340-8.
36. De Giorgi U, Rosti G, Papiani G, et al. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with cisplatin-refractory germ cell tumor: preliminary experience. Am J Clin Oncol. 2004;27:457-60.
37. Mardiak J, Sálek T, Sycová-Milá Z, et al. Gemcitabine plus cisplatin and paclitaxel in second-line treatment of germ cell tumors: a phase II study. Neoplasma. 2005;52:243-7.
38. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22:108-14.
39. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004;15:493-7.
40. De Giorgi U, Rosti G, Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory non-seminomatous germ cell tumor. Eur Urol. 2006; 50:1032-8.
41. Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002;20:1859-63.
42. Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25:513-16.
43. Miki T, Mizutani Y, Nonomura N, et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer. 2002;95:1879-85.
44. Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-relractory germ-cell tumor patients: a phase II study. Eur Urol. 2004;46:216-21.
45. Shamash J, Powles T, Mutsvangwa K, et al. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumors. Ann Oncol. 2007;18:925-30.
46. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10:789-99.
47. Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 2007;369:29-36.
48. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92.
49. Geyer CE, Foster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.
50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.
51. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
52. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24
53. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81.
54. Viglietto G, Romano A, Maglione D, et al. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of VEGF but not the placenta derived growth factor. Oncogene. 1996;13:577-87.
55. Fukuda S, Shirahama T, Imazono Y, et al. Expression of VEGF in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer. 1999;85:1323-30.
56. Jones A, Fujiyama C, Turner K, et al. Angiogenesis and lymphangiogenesis in stage 1 germ cell tumors of the testis. Br J Urol Int. 2000;86:80-6.
57. Bentas W, Beecken WD, Glienke W, et al. Serum levels of basic fibroblast factor reflects disseminated disease in patients with testicular germ cell tumors. Urol Res. 2003;30:390-3.
58. Aigner A, Brachmann P, Beyer J, et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 in serum of testicular cancer patients. Ann Oncol. 2003;14:1525-9.
59. Adam M, Schmidt D, Wardelmann E, et al. Angiogenic proto-oncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. Eur Urol. 2003; 44:329-36.
60. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study at bevacizumab/IFNα-2a vs. placebo/ IFNα-2a as first-line therapy in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 2007;25:3.
61. Mego M, Recková M, Sycova-Mila Z, et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol. 2007;18:962-3.
62. Izquierdo MA, Van der Valk P, Van Ark-Otte J, et al. Differential expression of the c-kit proto-oncogene in germ cell tumors. J Pathol. 1995;177:253-8.
63. Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the EGFR family in refractory germ cell cancer. Cancer. 2002;95:301-8.
64. Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and EGFR in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol. 2003;14:873-80.
65. Tian Q, Frierson HF Jr, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643-7.
66. Sakuma Y, Sakurai S, Oguni S, et al. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci. 2003;94:486-91.
67. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol. 2004;164:305-13.
68. McIntyre A, Summersgill B, Grygalewicz B, et al. Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005;65:8085-9.
69. Nakai Y, Nonomura N, Oka D, et al. KIT pathway is constitutively activated in human testicular germ cell tumors. Biochem Biophys Res Commun. 2005;337:289-96.
70. Looijenga LH, de Leeuw H, van Oorschot M, et al. Stem cell factor receptor codon 816 mutation predict development of bilateral testicular germ cell tumors. Cancer Res. 2003;63:7674-8.
71. Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 2002;3:655-64.
72. Piulats JM, Garcia del Muro X, Huddart R, et al. Phase II multicenter study of imatinib in patients with refractory germ cell tumors that express c-kit. Proc Am Assoc Cancer Res. 2007; 48:2648.
73. Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol. 2006;29:12-13.
74. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the EGFR underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-39.
75. Roelofs H, Mostert MC, Pompe K, et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol. 2000;157:1155-66.
76. Goddard NC, McIntyre A, Summersgill B, et al. KIT and RAS signaling pathways in testicular germ cell tumors: new data and review of the literature. Int J Androl. 2007;30:337-48.
77. Sommerer F, Hengge UR, Markwarth A, et al. Mutations of BRAF and RAS are rare events in germ cell tumors. Int J Cancer. 2005; 113:329-35.
78. Neuvians TP, Gashaw I, Hasenfus A, et al. Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue. Neoplasia. 2005; 7:446-56.
79. Kortsaris AH, Diamantopoulos N, Galaktidou G, et al. Relationship between IGF-1 and human testicular cancer. Proc Am Soc Clin Oncol. 2006;24:4586.
80. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic program for cancer and stem cells. Nat Rev Cancer. 2006; 6:637-45.
81. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343-50.
82. Kawakami T, Okamoto K, Sugihara H, et al. The MET proto-oncogene is not a major target for the gain of chromosome 7 in testicular germ-cell tumors of adolescents. Virchows Arc. 2004; 444:480-1.
83. Garcia A, Rosen L, Cunningham CC, et al. Phase I study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase II dose. Proc Am Soc Clin Oncol. 2007;25:3525.
84. Di Vizio D, Cito L, Boccia A, et al. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias to invasive germ cell tumors. Oncogene. 2005;24: 1882-94.
85. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124:1169-81.